Kyowa Hakko Kirin
Kyowa Kirin Co., Ltd. is a Japanese specialty pharmaceutical company focused on biotechnology research and development. The company concentrates its operational scope on core therapeutic areas, including nephrology, oncology, immunology, and rare diseases. Its key product offerings feature proprietary monoclonal antibodies and specialty drugs such as burosumab and mogamulizumab. Revenue drivers are primarily sales of proprietary prescription pharmaceuticals across global markets in Japan, North America, and Europe. Kyowa Kirin holds a strong international market position in antibody-based therapeutics. The company is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
29 of the funds FundTelligence covers report a position in Kyowa Hakko Kirin.
- Legal name
- Kyowa Hakko Kirin Co LTD
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 29
Funds holding Kyowa Hakko Kirin
- Danske Invest Japan Index Restricted — Danske Invest · 0.14 % (full portfolio disclosed, July 2026)
- Danske Invest Global Ansvarlig 80 — Danske Invest · 0.14 % (full portfolio disclosed, September 2026)
- Danske Invest Global Ansvarlig 65 — Danske Invest · 0.11 % (full portfolio disclosed, September 2026)
- Danske Invest Global Ansvarlig 50 — Danske Invest · 0.09 % (full portfolio disclosed, September 2026)
- Lannebo Marknad Japan — Lannebo · 0.08 % (full portfolio disclosed, June 2026)
- Danske Invest Global Ansvarlig 35 — Danske Invest · 0.07 % (full portfolio disclosed, September 2026)
- KLP AksjeAsia Indeks — KLP · 0.05 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 29 funds holding it.